- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4/A Registration of securities issued in business combination transactions
- 5.1 EX-5.1
- 10.41 EX-10.41
- 10.42 EX-10.42
- 10.43 EX-10.43
- 10.44 EX-10.44
- 10.45 EX-10.45
- 10.46 EX-10.46
- 10.47 EX-10.47
- 10.48 EX-10.48
- 10.49 EX-10.49
- 23.1 EX-23.1
- 23.2 EX-23.2
- 23.3 EX-23.3
- 99.1 EX-99.1
- 99.7 EX-99.7
- 99.8 EX-99.8
- 99.9 EX-99.9
- Download Excel data file
- View Excel data file
- 28 Mar 23 EFFECT Notice of effectiveness
- 24 Mar 23 POS AM Prospectus update (post-effective amendment)
- 7 Jun 21 EFFECT Notice of effectiveness
- 18 May 21 POS AM Prospectus update (post-effective amendment)
- 12 Feb 21 424B3 Prospectus supplement
- 12 Feb 21 EFFECT Notice of effectiveness
-
8 Feb 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 16 Oct 20 S-4 Registration of securities issued in business combination transactions
Exhibit 23.1
Independent Registered Public Accounting Firm’s Consent
We consent to the inclusion in this Registration Statement of Cancer Genetics, Inc. on Amendment No. 1 to Form S-4 (File No. 333-249513) of our report dated May 29, 2020, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audit of the consolidated financial statements of Cancer Genetics, Inc. as of December 31, 2019 and for the year ended December 31, 2019, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such Prospectus.
Our report on the consolidated financial statements refers to a change in the method of accounting for leases effective January 1, 2019 due to the adoption of the guidance in ASC Topic 842, Leases.
/s/ Marcum llp
Marcum llp
Houston, Texas
February 8, 2021